Evotec SE (NASDAQ:EVO) Short Interest Up 23.5% in June

Evotec SE (NASDAQ:EVO) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 195,500 shares, a growth of 23.5% from the May 31st total of 158,300 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 146,100 shares, the short-interest ratio is currently 1.3 days.

Analysts Set New Price Targets

EVO has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Evotec in a research report on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft upgraded Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Quadrant Capital Group LLC acquired a new position in shares of Evotec in the fourth quarter worth $25,000. Cetera Advisors LLC purchased a new stake in shares of Evotec during the 1st quarter worth about $188,000. Optiver Holding B.V. lifted its holdings in shares of Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after buying an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC bought a new stake in shares of Evotec in the 4th quarter valued at approximately $53,931,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Evotec Trading Up 1.9 %

Evotec stock traded up $0.09 during midday trading on Tuesday, reaching $4.95. The stock had a trading volume of 31,345 shares, compared to its average volume of 114,430. The firm’s fifty day simple moving average is $4.91 and its two-hundred day simple moving average is $7.07. Evotec has a twelve month low of $3.94 and a twelve month high of $13.49. The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.